Scholarlink

<p>Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with therapeutic outcomes often constrained by the complexity of the tumor microenvironment (TME). Comprising diverse cell types and signaling molecules, the TME is increasingly recognized as a critical determinant of tumor behavior and patient prognosis. Cancer-associated fibroblasts (CAFs), a dominant TME component, drive progression through intercellular communication. Although CAF-targeted therapies hold promise, the precise mechanisms underlying CAF–cancer cell interactions remain elusive. Leveraging single-cell sequencing, we identified ACTN1 as a gene highly expressed in CAFs and strongly correlated with NSCLC prognosis. We engineered an integrated hybrid nanovesicle composed of CAF membranes (cM) and a liposome core to encapsulate siRNA against ACTN1 (siACTN1). This represents the first CAF-membrane-coated siRNA system targeting ACTN1 for NSCLC therapy. The nanovesicles modulate cytokine secretion (IL-6 and CCL2) to inhibit NSCLC cell growth, migration, and invasion in vitro. In vivo studies corroborated these findings, demonstrating reduced cytokine secretion and attenuated tumor growth. By harnessing the intrinsic properties of CAFs for targeted siRNA delivery, these nanovesicles offer a novel strategy for TME modulation in NSCLC.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting tumor microenvironment with biomimetic nanovesicles for non-small cell lung cancer gene therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月1日

查看全文
  • Qihang Yan,
  • Li Gong,
  • Zihui Tan,
  • Zining Liu,
  • Xiaodong Li,
  • Dachuan Liang,
  • Jie Yang,
  • Kai Zhang,
  • Shuqin Dai,
  • Junye Wang

摘要

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with therapeutic outcomes often constrained by the complexity of the tumor microenvironment (TME). Comprising diverse cell types and signaling molecules, the TME is increasingly recognized as a critical determinant of tumor behavior and patient prognosis. Cancer-associated fibroblasts (CAFs), a dominant TME component, drive progression through intercellular communication. Although CAF-targeted therapies hold promise, the precise mechanisms underlying CAF–cancer cell interactions remain elusive. Leveraging single-cell sequencing, we identified ACTN1 as a gene highly expressed in CAFs and strongly correlated with NSCLC prognosis. We engineered an integrated hybrid nanovesicle composed of CAF membranes (cM) and a liposome core to encapsulate siRNA against ACTN1 (siACTN1). This represents the first CAF-membrane-coated siRNA system targeting ACTN1 for NSCLC therapy. The nanovesicles modulate cytokine secretion (IL-6 and CCL2) to inhibit NSCLC cell growth, migration, and invasion in vitro. In vivo studies corroborated these findings, demonstrating reduced cytokine secretion and attenuated tumor growth. By harnessing the intrinsic properties of CAFs for targeted siRNA delivery, these nanovesicles offer a novel strategy for TME modulation in NSCLC.

Graphical abstract